Status and phase
Conditions
Treatments
About
The primary objective of this study is to evaluate the similarity of the primary pharmacokinetic (PK) parameter AUC0-t of GB222 and bevacizumab after single administration; the secondary objective is to observe the safety and similarities and safety of other pharmacokinetic (PK) parameters (Cmax, AUC0-∞ etc.) and immunogenicity of GB222 and bevacizumab after single administration.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Exclusions:
Primary purpose
Allocation
Interventional model
Masking
84 participants in 2 patient groups
Loading...
Central trial contact
Shawn Yu, Master
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal